Daily Stock Analysis, IRWD, Ironwood Pharmaceuticals Inc, priceseries

Ironwood Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
10.64
Close
10.72
High
10.94
Low
10.52
Previous Close
10.66
Daily Price Gain
0.06
YTD High
15.21
YTD High Date
Feb 15, 2019
YTD Low
9.61
YTD Low Date
May 15, 2019
YTD Price Change
0.34
YTD Gain
3.28%
52 Week High
20.33
52 Week High Date
Jul 20, 2018
52 Week Low
9.07
52 Week Low Date
Dec 24, 2018
52 Week Price Change
-9.30
52 Week Gain
-46.45%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 8. 2017
15.60
Feb 24. 2017
16.41
11 Trading Days
5.21%
Link
LONG
May 9. 2017
16.94
May 30. 2017
17.97
14 Trading Days
6.06%
Link
LONG
Apr 9. 2018
15.87
Apr 24. 2018
17.09
11 Trading Days
7.72%
Link
LONG
Jun 28. 2018
18.95
Jul 18. 2018
19.91
13 Trading Days
5.05%
Link
LONG
Jan 4. 2019
11.00
Jan 22. 2019
12.19
11 Trading Days
10.85%
Link
Company Information
Stock Symbol
IRWD
Exchange
NasdaqGS
Company URL
http://www.ironwoodpharma.com
Company Phone
617-621-7722
CEO
Peter M. Hecht
Headquarters
Massachusetts
Business Address
301 BINNEY STREET, CAMBRIDGE, MA 02142
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001446847
About

Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. It discovers, develops and intends to commercialize differentiated medicines that improve patient's lives. Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook, Jr. and Gina Bornino Miller on January 5, 1998 and is headquartered in Cambridge, MA.

Description

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.